IGM Biosciences Inc IGMS.OQ IGMS.O is expected to show a fall in quarterly revenue when it reports results on March 5 (estimated) for the period ending December 31 2024
The Mountain View California-based company is expected to report a 39.5% decrease in revenue to $393.75 thousand from $651 thousand a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for IGM Biosciences Inc is for a loss of 74 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 9 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for IGM Biosciences Inc is $2.00, above its last closing price of $1.36.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.81 | -0.80 | -1.01 | Missed | -26.2 |
Jun. 30 2024 | -0.02 | -0.04 | -0.79 | Missed | -1,991.1 |
Mar. 31 2024 | -0.83 | -0.83 | -0.83 | Met | 0.2 |
Dec. 31 2023 | -0.96 | -1.03 | -1.01 | Beat | 2.2 |
Sep. 30 2023 | -1.18 | -1.21 | -1.04 | Beat | 14.3 |
Jun. 30 2023 | -1.44 | -1.43 | -1.43 | Met | 0.3 |
Mar. 31 2023 | -1.34 | -1.36 | -1.33 | Beat | 2.5 |
Dec. 31 2022 | -1.25 | -1.19 | Beat | 4.5 |
This summary was machine generated March 3 at 12:08 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。